Herceptin (trastuzumab)

All enrolled patients received the full treatment protocol consisting of anthracycline followed by 12 months of trastuzumab alone or with pertuzumab. The highest risk was observed when both elevated hs-Tn I (≥82 ng/L after four cycles of anti-HER2 agents) and elevated hs-CRP (after four cycles of anthracyclines) were present. The interaction between both hs-Tn I and hs-CRP demonstrates significant predictive value for cardiotoxicity risk related to HER2+ breast cancer treatment.

P2, N=13, Terminated, Spanish Breast Cancer Research Group | Trial completion date: Aug 2026 --> May 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> May 2025; The study was closed early due to safety concerns and an unfavorable benefit-risk balance. Unexpected high neutropenia rates required a costly sub-study, which was not feasible, forcing the sponsor to terminate the trial prematurely.

Tucatinib addition to trastuzumab and pertuzumab demonstrated improvement in PFS with no new safety signals identified and may be an option for 1L maintenance therapy in patients with HER2+ MBC.

Both HER2 and ESR1 are determinant of KN026 efficacy in advanced HER2-positive breast cancer, implying the potential of KN026 combined with endocrine therapy in HER2- and ER-positive breast cancer.

Chemotherapy-free regimens demonstrate promising responses and survival outcomes in patients with HER2-positive early breast cancer. However, the combination of anti-HER2 drugs with chemotherapy still demonstrates superior overall clinical outcomes.

This outcome highlights the potential benefits of comprehensive approaches and the feasibility of proactive local interventions for oligoprogressive disease. This case provides valuable experience for managing similar cases and offers new ideas for combining novel modalities like antibody-drug conjugates (ADC) drugs, immunotherapy, and radiotherapy.

Large-scale phase III clinical trials are needed to verify the efficacy of combined neoadjuvant treatment application for GC.

P2, N=45, Active, not recruiting, Shanghai Zhongshan Hospital | Not yet recruiting --> Active, not recruiting

P2, N=26, Recruiting, The First Affiliated Hospital with Nanjing Medical University

Trastuzumab-based therapy has shown survival benefit in HER2-positive SEC, leading to its inclusion in current treatment guidelines...The prognostic value remains debated, though recent trials of antibody-drug conjugates (e.g., T-DXd) show promise...Diagnostic challenges include variable scoring systems, intratumoral heterogeneity, and HER2-low classification. Standardization of testing criteria and further clinical validation of HER2-targeted strategies across gynecologic tumors are essential to guide personalized therapy and improve outcomes.

18F-FDG PET-CT before and after the first cycle of neoadjuvant treatment does not appear to be an effective tool to predict pCR in patients with HER2+ BC.